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This review summarizes advances in our understanding of the biochemical events which underlie the remarkable neurotoxic action of MPTP (1- 
methyl-4-phenyl-l-l,2,3,6-tetrahydropyridine) an  the parkinsonian symptoms it causes in primates. The initial biochemical event is a two-step 
oxidation by monoamine oxidase B in glial cells to MPP + (1-methyl-4-phenylpyridinium). A large number of MPTP analogs ubstituted in the 
aromatic (but not in the pyridine) ring are also oxidized by monoamine oxidase A or B, is in some cases faster than any previously recognized 
substrate. Alkyl substitution at the Z-position changes MPTP, a predominantly B type substrate, to an A substrate. Following concentration i
the dopamine neurons by the synaptic system, which has a high affinity for the carrier, MPP + and its positively charged neurotoxic analogs are 
further concentrated by the electrical gradient of the inner membrane and then more slowly penetrate the hydrophobic reaction site on NADH 
dehydrogenase. Both of the latter events are accelerated by the tetraphenylboron a ion, which forms ion pairs with MPP + and its analogs. Mito- 
chondrial damage isnow widely accepted as the primary cause of the MPTP induced eath of the nigrostriatal cells. The molecular target of MPP ÷, 
its neurotoxic product, is NADH dehydrogenase. R cent experiments suggest that the binding site is at or near the combining site of the classical 
respiratory inhibitors, rotenone and piericidin A. 
Monoamine oxidase; MPTP (l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Neurotoxin; NADH dehydrogenase 
1. INTRODUCTION 
In an earlier Trends Biochem. Sci. review [1] we sum- 
marized how the sudden appearance of  parkinsonism in 
relatively oung patients in the San Francisco Bay Area 
in 1982 was traced to their use of  a designer drug, 'new 
heroin' ,  manufactured by a clandestine laboratory, and 
to the MPTP  contained in defective batches of  the street 
drug. Almost immediately following the reports that 
MPTP  is neurotoxic to humans [2], subhuman primates 
md mice [3-5], eliciting damage to dopaminergic 
aeurons, it was shown that MPP  + (1-methyl-4-phenyl- 
pyridinium) is the neurotoxic form and that it arises by 
4-e oxidation of  MPTP  in brain mitochondria [6]. 
P roo f  that the enzyme responsible for processing 
MPTP  is monoamine oxidase (MAO B) in the glial 
cells, o f  which it is an excellent substrate and that MAO 
A also oxidizes MPTP ,  albeit more slowly, was re- 
ported soon thereafter [7]. Deprenyl, a selective, 
mechanism-based inhibitor of  MAO B, prevented the 
oxidation of  MPTP  by pure MAO B and protected ex- 
perimental animals f rom the neurotoxic action of  
MPTP .  
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The biochemical events which follow the passage of  
MPTP  through the blood-brain barrier, as visualized in 
1987, are summarized in Scheme I. The first step in the 
development of  neurotoxicity is thus oxidation by 
MAO B in the astrocytes of  the brain to the 
dihydropyridinium form (MPDP +), which is then fur- 
ther oxidized in part by this enzyme, in part nonen- 
zymically to the pyridinium form, MPP  + [8]. The 
MPP  + is selectively taken up by the dopamine reuptake 
system at dopaminergic synapses and probably pumped 
into the stroma of  the neurons [9]. MPP  + is then con- 
centrated from the cytoplasm into the mitochondrial 
matrix by the electrochemical gradient of  the inner 
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Scheme 1. Steps in the expression of the neurotoxicity of MPTP.  
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depletion death 
membrane, where it combines with NADH dehydro- 
genase, probably at the dehydrogenase-Q junction, 
blocking thereby electron transport [10-12]. This leads 
to cessation of ATP synthesis, nigrostriatal cell death, 
and the consequent neurological symptoms 
characteristic of parkinsonian patients. Some questions 
remained, such as whether MPP ÷ was the only or even 
the main neurotoxic product arising from MPTP, why 
there were remarkable differences in species ensitivity 
to MPTP, or why organs other than the brain are not 
damaged by MPTP. However, most of the debate 
centered around the 'mitochondrial hypothesis', name- 
ly that, despite their dissimilar structures, MPP ÷ acts 
like rotenone to inhibit mitochondrial respiration ver- 
sus the 'oxidative stress' hypothesis, which assumes that 
the effects of hydroxyl and superoxide radicals caused 
nigrostriatal cell death. The ultimate question, which 
remains open, is whether the similarity in neuronal le- 
sions and neurological symptoms elicited by MPTP and 
its congeners and those seen in idiopathic parkinsonism 
suggests that evironmental compounds of related struc- 
ture may be causative agents in human parkinsonism 
[13-14]. The present review summarizes recent ad- 
vances in these areas and other advances of interest o 
the biochemical community. 
2. BIOACTIVATION 
The first step in the formation of neurotoxic products 
from MPTP is oxidation by monoamine oxidase 
(MAO) B in the brain. Studies during the past 3 years 
have established that several neurotoxic MPTP analogs 
are also rapidly oxidized by MAO A, while yet others 
are processed almost entirely by the A form (Table I). 
The specificity pattern shown in Table I for the pure en- 
zymes [15] holds equally well for intact brain mitochon- 
dria [16]. It is seen that substitution at 2' in the 
aromatic ring greatly enhances the rate of oxidation by 
MAO A: the longer the side chain, the better substrate 
it becomes. In contrast, oxidation by MAO B pro- 
gressively decreases with the length of the alkyl substi- 
tuent beyond 2'-methyl-MPTP. In accord with this, 
while the toxicity of MPTP to sensitive species is com- 
pletely prevented by selective inhibitors of the B en- 
zyme, such as deprenyl, protection from 2'-methyl 
MPTP requires both MAO A and B inhibitors 
(clorgyline and deprenyl), and clorgyline alone protects 
from the neurotoxic effects of 2'-ethyl MPTP. This 
gratifying agreement between biochemical and phar- 
macological studies uggests the generalization that in 
order for a tetrahydropyridine to be neurotoxic, it must 
be oxidized by either MAO A or B. 
The mechanism by which MPDP ÷, the primary ox- 
idation product of MPTP, is further oxidized to MPP ÷ 
in the cell remains uncertain. At relatively high concen- 
trations and alkaline pH, MPDP ÷ disproportionates o 
MPP ÷ and MPTP, but the reaction is not likely to be 
significant at the intracellular concentrations prevailing 
in MPTP-treated animals. Slow non-enzymic oxidation 
by molecular 02 has also been observed. Both MAO A 
and B were shown [8] to oxidize MPDP ÷ and its 
analogs relatively slowly, the rate in each case being two 
orders of magnitude l ss than the values hown in Table 
I. In brain mitochondria the oxidation is sensitive to 
MAO B inhibitors, but it has been reported to be insen- 
sitive in hepatocytes [17], perhaps because of the 
Table I 
Oxidation of MPTP and its analogs by pure MAO 
Turnover number/Kin 
Substrate MAO A MAO B 
Control 1283 1064 
MPTP 143 523 
2' -Methyl-MPTP 593 1275 
2' -Ethyl-MPTP 688 295 
2' -n-Propyl-MPTP 658 86 
2' -Methoxy-MPTP 511 233 
2' - Isopropyl-MPTP 1131 51 
2' ,6' -Dimethyl-MPTP 490 209 
3' -MethyI-MPTP 76 650 
2' -Fluoro-MPTP 100 1054 
2' -Chloro-MPTP 400 1353 
3' -Fluoro-MPTP 391 900 
3 ' -Chloro-MPTP 567 1132 
3' -Bromo-MPTP 300 2036 
3' -Methoxy-MPTP - 944 
4' -MethyI -MPTP 58 345 
4' -Fluoro-MPTP - 423 
4' -Chloro-MPTP 69 595 
4' -Amino-MPTP 12 54 
4' -Nitro-MPTP 185 16 
EPTP 28 200 
MCTP 270 688 
M(4Bz)TP 100 2675 
M(4tBu)TP 92 
PPTP  73 31 
2' -Trif luoromethyl-MPTP 169 520 
3 ' -Trif luoromethyl-MPTP 214 514 
MTHIQ* 0 0 
1 -methyl-4(2-pyridinyl)-Tp 19 41 
1-methyl-4(1-CH~-2-pyrroyl)-Tp 534 347 
The control substrates were kynuramine for MAO-A and 
benzylamine for MAO-B. Although this isoquinoline is not oxidized, 
it is a competitive inhibitor of  both enzymes. 
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numerous catabolic reactions occuring in liver but not 
in brain. 
3. CONTRIBUTIONS TO THE BIOCHEMISTRY 
OF MONOAMINE OXIDASES 
Perhaps the most significant new information deriv- 
ed from these studies concerns the substrate specificities 
of MAO A and B. Several laboratories have studied the 
oxidation of synthetic analogs of MPTP [18-20]. As 
seen in Table I, 2' -methyl-MPTP, 2' -C1-MPTP, 3' -C1- 
MPTP, and 1-methyl-4-benzyl-tetrahydropyridine are 
all better substrates of MAO B than benzylamine, 
previously the best substrate known. In the case of 
MAO A, 2'-isopropyl-MPTP is nearly as good a 
substrate as kynuramine, previously believed to be its 
most rapidly oxidized substrate, while the turnover 
number of 2'-n-propyl-MPTP (250 at 30°C) is con- 
siderably higher than that of kynuramine (154), 
although the ratio of turnover number/Kin favors 
kynuramine because of its lower Km value. Other 
studies have shown that 2'-F-MPTP, 2'-CF3-MPTP, 
and 3'-CF~-MPTP are excellent substrates of MAO B 
but not of A, while 1-CH3-4(1-CHr2-pyrroyl)-tetrahy- 
dropyridine is a good substrate of both forms. 
In addition to irreversible inactivation, MAO A and 
B are reversibly inhibited by the products of MPTP ox- 
idation (MPDP ÷ and MPP ÷ [21]. Subsequent s udies 
on a large series of MPP ÷ analogs howed that, as in 
the case of MPP 4, the A enzyme is far more sensitive 
to reversible inhibition than the B form [15]. Very re- 
cent studies [22] demonstrated that 4'-alkyl substituted 
MPP ÷ analogs are particularly effective competitive in- 
hibitors of MAO A. Thus, the Ki values ~M) for MAO 
at 30°C are: MPP ÷ (3.0), 4'-methyl-MPP ÷ (0.2), 
4'-n-pentyl-MPP ÷ (0.13), 4'-n-heptyl-MPP ÷ (0.59), 
4'-n-pentyl-azido-MPP ÷ (0.075). The corresponding 
Ki values for MAO B range from 32 to 230 ttM. 
Plasma amine oxidase has been reported [23] not to 
oxidize MPTP or 16 of its analogs tested, although 
most of them are moderately good reversible inhibitors 
of the enzyme. 
The serendipitous circumstance that MPDP÷, the 
product of the first 2-e oxidation of MPTP, is chemical- 
ly stable, in contrast to the imines formed from primary 
and secondary amines, has permitted reexamination f 
the kinetic mechanism of MAO B [24]. The widely held 
concept that flavoprotein oxidases, including MAO B, 
operate either by a binary or a ternary complex 
mechanism, depending on the substrate, had to be 
modified, because the enzyme can operate by three 
alternate mechanisms, a binary complex, and two ter- 
nary complexes of reduced enzyme-O2-product, and 
reduced enzyme-O2-substrate andthese are not mutual- 
ly exclusive but may occur concurrently. Recently, ex- 
tension of this work to MAO A revealed that it operates 
by both a binary complex (ping-pong) mechanism and 
by a ternary complex involving reduced enzyme- 
substrate-O2, not product (MPP÷) that leads only to 
formation of a dead-end complex [25]. 
The fact that MPTP and its analogs undergo two 2-e 
oxidation steps by MAO A and B, each of which is ac- 
companied by mechanism-based inactivation, has of- 
fered a unique opportunity to explore the 
characteristics of mechanism-based inactivation of en- 
zymes in sequential reactions. Early studies [8] in- 
dicated that the rate of inactivation of MAO B by 
MPTP and MPDP ÷ were identical, suggesting that 
processing of the latter compound was responsible for 
the irreversible loss of activity. Recent studies [26], us- 
ing a rapid scan spectrophotometer and a multi- 
component analysis program, confirmed that the 
mechanism-based inactivation of MAO B by the 
dihydropyridinium is faster than inactivation by the 
tetrahydropyridinium for MPTP and several analogs, 
whereas the reverse is true of MAO A, which processes 
MPDP ÷ and its analogs poorly. Ottoboni et al. [27] 
also came to the conclusion that the mechanism-based 
inactivation of MAO B in the course of MPTP oxida- 
tion is primarily due to the second 2-e oxidation. These 
authors also concluded, on the basis of kinetic 
deuterium isotope effect measurements, hat the rate 
determining step in MPTP oxidation by MAO B is C-H 
cleavage and thus its mechanism ore likely involves a 
hydrogen atom abstraction than deprotonation of an 
iminium radical. 
4. IS MPP ÷ NEUROTOXIC PRODUCT OF MPTP 
METABOLISM? 
Soon after the discovery that MPTP is metabolized 
to MPDP + and MPP ÷ in the brain, several ines of 
evidence pointed to MPP ÷ being the main neurotoxic 
product. Perhaps the most persuasive evidence was the 
high affinity of MPP ÷ (but not of MPDP+) for the 
dopamine carrier (dopamine reuptake system), the pro- 
tection from the neurotoxicity of MPTP by mazindol 
[9,28], a specific inhibitor of this carrier, and the selec- 
tive toxicity of MPP ÷ to dopaminergic neurons in 
culture [29]. Castagnoli's group [30] also considered 
that MPDP ÷ or a ring-opened form of it might alkylate 
proteins and contribute to neurotoxicity. Recent studies 
[31], however, ruled out covalent binding of MPTP 
metabolites in vivo as relevant o toxicity. At this 
writing, then, consensus seems to have been reached im- 
plicating MPP + as the primary neurotoxic form. 
5. THE OXIDATIVE STRESS HYPOTHESIS 
One of the two main hypotheses for the ultimate 
cause of the destruction of dopaminergic neurons by 
MPP ÷ held that superoxide and hydroxyl radicals 
generated uring intracellular reduction and reoxida- 
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tion of MPP ÷ were responsible, akin to the action of 
the herbicide, Paraquat. Although the comparison was 
inappropriate, because the low redox potential of 
MPP ÷ ( -  1.07 V) precludes reduction in the cell, the 
hypothesis remains popular with some biologists [32]. 
However, there is evidence that, in contrast to MPTP 
induced parkinsonism, the idiopathic disease due to the 
progressive decline in the number of nigrostriatal 
neurons on aging is due to the free radicals produced in 
the MAO B-catalyzed oxidation of dopamine in aged 
animals, which have increased levels of MAO B, owing 
to the proliferation of glial cells [33,34]. Evidence sup- 
porting the oxidative stress hypothesis has always been 
indirect; e.g. that MPTP lowers glutathione in 
dopamine neurons, or that glutathione and antiox- 
idants protect from the neurotoxicity of MPTP. These 
reports could not be confirmed in subsequent s udies 
[35,36]. Perhaps the most decisive evidence against he 
oxidative stress hypothesis has come from the 
demonstration [37] that anti-oxidants do not protect 
dopamine neurons in culture from MPP ÷ 
6. THE MITOCHONDRIAL HYPOTHESIS 
The hypothesis that the neurotoxic effect of MPP + is 
the result of shutting off mitochondrial respiration and, 
hence, oxidative phosphorylation byinhibiting NADH 
dehydrogenase at the same site as rotenone and bar- 
biturates [38], has received impressive support in recent 
years. Using dissociated dopamine neurons in culture, 
Sanchez-Ramos et al. have demonstrated that the bar- 
biturate pentothal protects dopamine neurons in culture 
against MPP ÷ [37]. Moreover, MPP ÷ caused extensive 
oxidation of cytochrome b in rat striatal slices, as ex- 
pected if the toxin interrupted electron flux from 
NADH dehydrogenase to Q. More recent evidence has 
come from the finding of mitochondrial bnormalities 
in the nigral neurons of MPTP treated monkeys [39] 
and Complex I deficiency in the nigrostriatum of 
parkinsonism patients [40,41]. The fact that MPP ÷ and 
its analogs compete with the respiratory chain in- 
hibitors rotenone and piericidin for binding to NADH 
dehydrogenase (cf. section 9) provides further, strong 
support for this hypothesis. 
7. FROM ACCUMULATION IN MITOCHONDRIA 
TO CELL DEATH 
In order for MPP ÷ to inhibit NADH dehydrogenase 
extensively, it must be concentrated from the estimated 
30 #M cytoplasmic concentration seen in MPTP-treated 
rodents to millimolar levels in the mitochondria [12]. 
This concentration is rapidly reached in response to the 
electrical gradient across the membrane, Some 
characteristics of the uptake initially suggested that the 
process might be carrier-mediated [1], but studies using 
charged and uncharged structural analogs indicated 
passive Nernstian transport, as for other lipophilic ca- 
tions [42]. Interpretation of the process was further 
complicated by the fact that various MPP ÷ analogs ac- 
cumulated tovery different levels in the mitochondrion, 
depending on their structures [43]. 
The confusion was resolved by the demonstration 
that the lipophilic anion, tetraphenylboron (TPB-), 
which carries cations into hydrophobic environments 
by ion-pairing, dramatically enhances the inhibition of 
mitochondrial respiration by MPP + [44-46]. The 
remarkable potentiation of MPP ÷ toxicity to 
mitochondria by trace amounts of TPB- (up to 
1000-fold with some MPP ÷ analogs) is the result of at 
least two distinct processes (Scheme 2). TPB- ac- 
celerates the passage of MPP ÷ across the inner mem- 
brane and raises the matrix concentration 2-4-fold. 
However, this does not fully account for the 
102-103-fold lowering of the IC5o value for the inhibi- 
tion of mitochondrial respiration. The second effect 
was noted [41,45] in studies of inverted sub- 
mitochondrial particles, in which the rotenone site of 
NADH dehydrogenase i  xposed to the cytoplasm. In 
such preparations TPB- potentiated the inhibitory ef- 
fect of MPP ÷ by one order of magnitude and that of 
some MPP ÷ analogs by 2 orders of magnitude. This 
suggests that ion pairing between MPP + and TPB- 
helps the penetration i to the hydrophobic pocket on 
the dehydrogenase where MPP÷, rotenone, and bar- 
biturates are thought to combine. The neutral 
4-phenylpyridine molecule, although a much better in- 
hibitor than MPP ÷ in submitochondrial particles, is a 
poor inhibitor in intact mitochondria (because it is not 
concentrated bythe electrical gradient) and its effect is 
not potentiated by TPB-.  Moreover, 4'-heptyl- 
MPP +, a hydrophobic molecule, is ~- 1000 times more 
inhibitory than MPP + in submitochondrial particles, 
but TPB- does not potentiate its action, perhaps 
because it can penetrate the hydrophobic site unaided 
owing to its pronounced lipophilicity. 
8. STRUCTURAL REQUIREMENTS FOR IN- 
HIBITION 
If the inhibition of State 3 respiration in mitochon- 
dria by MPP ÷ is due to a specific block between the 
highest potential Fe-S cluster of NADH dehydrogenase 
and Q (Fig. 1), then all MPP ÷ analogs which are good 
inhibitors of respiration i mitochondria should also be 
effective inhibitors of NADH oxidation in inverted 
membranes. With over 20 MPP ÷ analogs tested, this 
was true in each case [43]. Thus, 4'-methyl-MPP ÷ is 
much more potent than MPP ÷ in mitochondria; its 
IC50 value for inhibiting NADH oxidase activity in sub- 
mitochondrial particles (ETP) is 10 times lower than 
that of MPP ÷. The 4'-methyl, 4'-n-propyl, 4'-n- 
pentyl, and 4'-heptyl analogs are increasingly more po- 
tent in both systems. 











Intramitochondrial bindin$ site Inhibition of 
MPP + NADH dehydrogenase 
(>I0 mM) 
Scheme 2. Fate of  MPP ÷ after being pumped 
Step 2 
into the neuron. Both steps are accelerated by TPB- .  
There are a number of pyridines, however, which are 
good inhibitors in submitochondrial p rticles but not in 
intact mitochondria. The familiar example is 4-phenyl- 
pyridine, as discussed above. MPTP, 4-phenylpiperi- 
dine, and other uncharged analogs behave similarly. 
Measurement of the accumulation of labeled MPP ÷ 
analogs by the mitochondria explains in the majority of 
cases the lesser effectiveness of a compound in in- 
hibiting mitochondrial respiration [43]. An exception to 
this is 1,1-dimethyl-4-phenyltetrahydropyridinium, a 
reasonably good inhibitor in submitochondrial par- 
ticles, appreciably but slowly concentrated in the 
mitochondria, which, nevertheless, has no measurable 
effect on mitochondrial respiration after a 5 min in- 
cubation [43]. The reason in this case has been shown to 
be the cumulative ffect of slow penetration both into 
the mitochondria and, particularly, to the hydrophobic 
binding site on NADH dehydrogenase, since the 
presence of 10 #M TPB- greatly enhances its inhibitory 
effect in submitochondrial p rticles and brings about a 
dramatic rise in its toxicity to mitochondrial respira- 
tion. Thus, for an MPP ÷ analog to be a good inhibitor 
of NAD-linked oxidations in mitochondria, it must be 
positively charged at neutral pH, concentrated by the 
electrical gradient and able to penetrate the 
hydrophobic rotenone site on NADH dehydrogenase. 
9. IDENTIFICATION OF THE BINDING SITE ON 
NADH DEHYDROGENASE 
When EPR studies [47] suggested that the target of 
MPP ÷ is between the highest potential Fe-S cluster of 
NADH dehydrogenase and Q, as for rotenone, bar- 
biturates, and piericidin A, the exciting possibility arose 
that all these inhibitors are bound at or near the same 
site. With the advent of MPP ÷ analogs with very low Ki 
values for NADH dehydrogenase, uch as the 4'-alkyl 
derivatives, direct testing of this hypothesis became 
possible. Thus, the Ki values range from 680/zM for 
4'-methyl-MPP + to 4 #M for 4'-n-decyl-MPP +, the 
latter approaching the Ki for rotenone. All but the n- 
heptyl and n-decyl analog nevertheless dissociate on 
dilution, so that they may be completely removed by 
centrifugation and washing of submitochondrial par- 
ticles, with resultant recovery of the activity, whereas 
piericidin A remains firmly (but non-covalently) bound 
at the specific site during such treatment, and rotenone 
dissociates only partly during several cycles of cen- 
trifugation and resuspension in sucrose-serum albumin. 
This difference in the dissociation of the enzyme- 
inhibitor complexes permitted the demonstration that 
MPP ÷ analogs prevent the binding of rotenone and of 
piericidin A to NADH dehydrogenase and thus protect 
the enzyme from their powerful inhibitory effect 
[48,49]. Fig. 2 shows that, at a low concentration of
piericidin prior to treatment with 4'-methyl, 4'-n-pro- 
pyl, and 4'-n-pentyl-MPP ÷ effectively protects the en- 
zyme from inhibition by piericidin A and t-butyl- 
MPP ÷ (1 mM) completely prevents the inhibition. In 
Tabel III, [14C]piericidin A was used to illustrate the 
fact that the prevention of piericidin binding parallels 
protection from piericidin inhibition MPP ÷ and 
.H* MPP  + nH ÷ nH ÷ 
NAD÷"~r 
2H ÷ + -,yo, ~o  
SUCClNATE 
I DEHYOROGENASE 
J ( 3 Fe-S clusters 
SUCCINATE 
Fig. I. Hypothetical reaction site of MPP + in the respiratory chain. 
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Table II 
Inhibition of NADH oxidase activity in submitochondrial particles 
by 4'-alkyl analogs of MPTP ÷ 
IC5o (#M) 
Substituent - TPB- + TPB- 
H 5000 700 
4' -methyl 680 190 
4' -propyl 200 30 
4' -t-butyl 140 3 
4' -pentyl 45 12 
4' -heptyl 6 6 
4' -decyl 4 4 
ETP (2 mg/ml) was preincubated for 5 min at 30°C with various 
concentrations of the inhibitor. TPB - (10/~M) was added to enhance 
penetration of the analog into the hydrophobic site. 
various 4'-alkyl analogues. Similar results were ob- 
tained using 4'-alkyl-MPP ÷ analogs to protect NADH 
dehydrogenase from inhibition by and binding of 
rotenone [48,49]. 
A logical extension of these studies, now in progress 
in our laboratory, will be the identification of the pep- 
tide involved in binding these inhibitors, using photoaf- 
finity labeling with 4'-azido-3[H]MPP ÷.
10. ENDOGENOUS NEUROTOXINS RELATED 
TO MPTP 
Continued interest in the biochemistry of MPTP has 
also triggered an ongoing search for structurally 
related, endogenous compounds which might be involv- 
Protection against piericidin inhibition 
by 4'-analogs (ImM, IO/~M TPB-) 
'1 
None IvlF9 + 4'-Me ,g-t-lint ~Pent ~he~t 
Analogs 
Fig. 2 Protection of NADH dehydrogenase against piericidin 
inhibition by 4'-alkyl-MPP ÷ analogs. The experiment was 
conducted by incubation submitochondrial particles (ETP) with 0.4 
/~M piericidin with or without 1 mM MPP ÷ analogs and 10 /zM 
TPB- .  The latter served to increase penetration of the positively 
charged analogs into the target site. The suspension was then washed 
by centrifugation with 2% bovine serum albumin (BSA)/0.25 M 
sucrose/0.25 M phosphate, pH 7.4, so as to remove spuriously bound 
piericidin as well as the 4'-alkyl-MPP + analogs. Under these 
conditions all MPP ÷ analogs are removed, except for 4'-heptyl- 
MPP ÷, which is incompletely washed out. 
ed in the etiology of parkinsonism. Recent studies in 
Japan have concentrated on isoquinolines. Thus, 1, 2, 
3, 4-tetrahydroisoquinoline (TIQ) and its 1-methyl 
derivative (1-Me-TIQ) have been detected in human 
[50] and rat [51] brain. TIQ has been reported to cause 
parkinsonism in primates, and to inhibit NADH 
dehydrogenase and tyrosine decarboxylase (involved in 
the synthesis of dopamine) in rodent brain prepara- 
tions. Since TIQ is widely distributed in foods, it may 
not be an endogenous compound. Naoi et al. [52] sug- 
gest that the 1-methylisoquinolinium ion is the toxic 
form, derived from TIQ by methylation via N- 
methyltransferase to 1-Me-TIQ, followed by MAO- 
catalyzed oxidation. In our hands, however, 1-Me-TIQ 
is not oxidized by pure MAO A or B or by brain 
mitochondria. Moreover, if the activity of N- 
methyltransferase in the brain were sufficient for the 
role postulated above, one wonders why 
4-phenylpyridine is not neurotoxic by virtue of methyla- 
tion to MPP ÷. 
Methylation of metabolic derivatives of indoleamines 
and tryptophan yields B-carbolines which resemble 
MPP ÷ with a nitrogen bridge between the two rings. 
Acute administration of these compounds produced 
behavior changes and decreased opamine levels in 
monkeys, but not persistent parkinsonism. 2-Methyl 
harmine is as toxic as MPP ÷ to cells in culture [53], so 
may well be a candidate for long-term effects. 
11. RELATION TO IDIOPATHIC PARKINSONISM 
While some differences have been observed in the 
histopathology of idiopathic parkinsonism and the 
MPTP-induced isease in primates, the similarities are 
more impressive than the differences. The signs of a 
chronic disease which develops over a period of years or 
decades might be expected to differ from those rapidly 
appearing after MPTP injection. Few would deny that 
MPTP may not only provide a useful model for the 
human disease but might also yield clues to the identity 
of environmental xenobiotics related to the etiology of 
parkinsonism. At this point it seems clear that for an 
environmental tetrahydropyridine to be acutely 
neurotoxic, it must be oxidized by MAO A or B, 
pumped into the dopamine neurons by the carrier, and 
inhibit mitochondrial respiration on NAD-linked 
substrates. If one of these requirements is not met but 
the compound inhibits NADH oxidase, it might still be 
a chronic, cumulative neurotoxin, as has been proposed 
for 4-phenylpyridine. 
The exciting studies with MPTP world-wide have had 
another, more immediate benefit for the treatment of 
parkinsonism in that they stimulated clinical trials of 
selegiline (deprenyl) in the USA and its therapeutic use 
[54]. Building on earlier observations in Europe that the 
use of this MAO B inhibitor in conjunction with L- 
DOPA prolongs the life of parkinsonian patients, well- 
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Table II1 
Protection of NADH dehydrogenase by4'-alkyl-MPP ÷ analogs from piericidin binding and inhibition 
November 1990 
Analog Concentration (mM) Activity remaining Protection (070) Bound inhibitor Protection 
remaining 
None 7.14 0 1.66 0 
4' -Me-MPP + 10 46 42 0.99 40 
4' -Pr-MPP ÷ 1.5 68 66 0.61 63 
4' -Pe-MPP ÷ 0.45 75 73 1.25 75 
4'-t-Bu-MPP ÷ 0.06 16 10 1.31 21 
4'-hept-MPP ÷ 0.03 3.6 0 1.6 0 
The experiment was carried out as in Fig. 2, except hat [14C]piericidin was used at 0.52/zM concentration a d the concentration f the MPP + 
analogs was varied. TPB- was present at 10 #M concentration. The results represent [14C]piericidin a d activity remaining after 3 washes of the 
particles with 2°/o BSA/0.25 M sucrose/0.025 M phosphate, pH 7.4. NADH oxidase activity and piericidin binding are in arbitrary units. 
contro l led studies with early park insonian patients pro-  
v ided highly signif icant data demonstrat ing that 
selegiline alone delays the progress o f  the disease and 
the need for L -DOPA treatment.  
12. SOME UNRESOLVED PROBLEMS 
Despite the impressive advances in understanding of  
the events which fol low the systemic administrat ion of  
MPTP ,  a number of  interesting questions remain 
unanswered.  Some of  the seemingly confl ict ing reports 
result f rom extrapolat ing experiments on one organ or 
one type of  cell to a very di f ferent one, or to arguing 
f rom chemical experiments conducted under condit ions 
far f rom those l ikely to occur in the cell to what might 
happen in vivo. 
The variety of  detoxifying reactions occurr ing in 
other organs but absent f rom neuronal  tissue has often 
been invoked as one explanat ion for the resistance of  
ceils f rom liver, k idney etc., to irreversible damage by 
MPTP  in vivo. Whi le the degree to which cytochrome 
P-450 and flavin containing monooxygenase detoxi fy 
MPTP  in such tissues is uncertain [55,56], it is clear that 
MPP  ÷ accumulat ion is far less extensive than in 
neurons.  The rapid removal  of  the toxic MPP  ÷ from 
the circulat ion in part  by sequestrat ion in adrenal  
chromaf f in  vesicles, seems to provide addit ional  protec- 
t ion [57]. Moreover,  unl ike neurons, other cells may 
survive mitochondr ia l  in jury by their abi l i ty to form 
ATP  anaerobical ly  and to regenerate. There is no ques- 
t ion, however, that in vitro even hepatocytes can be kill- 
ed by MPTP  under appropr ia te  condit ions.  The most 
impor tant  reason for the selective ffect by MPTP  in 
ki l l ing dopamine neurons still seems to be the act ion of  
the dopamine carrier which concentrates MPP ÷ in 
these neurons. 
A related question is the reason for the differences in 
susceptibi l i ty of  di f ferent species to irreversible damage 
by MPTP .  The hypothesis remains viable that the most 
susceptible species (man, subhuman pr imates,  C57 
black mice) contain neuromelanin,  which binds MPP ÷ 
and may serve as a depot for it, whereas rats, and other 
resistant species lack it. Another  interesting hypothesis 
impl icates the high MAO B activity o f  the capi l lary wall 
in rats, in contrast o species ensitive to MPTP .  A pro-  
tective effect could come from oxidat ion o f  MPTP  at 
the b lood-bra in  barr ier,  so that the charged product  
cannot  pass. The possibi l i ty that the resistance of  rats to 
irreversible neuronal  damage by MPTP  may be a func- 
t ion of  slow penetrat ion into the brain is compat ib le  
with the f inding that the stereotaxic administ rat ion of  
MPP  ÷ to the n igrostr iatum of  rats results in lactate ac- 
cumulat ion  and other evidence of  mitochondr ia l  in jury 
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